Delving into the Latest Updates on Xinkaiyiyao Science & Technology Shanghai Co. Ltd. with Synapse

Overview

Tags

Urogenital Diseases

Immune System Diseases

Endocrinology and Metabolic Disease

Small molecule drug

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Immune System Diseases	2
Endocrinology and Metabolic Disease	1
Infectious Diseases	1

Top 5 Drug Type	Count

Small molecule drug	3

Top 5 Target	Count

DHODH(Dihydroorotate dehydrogenase)	1
RT(Viral reverse transcriptase)	1
VDR(Vitamin D receptor)	1

1. To evaluate the safety and efficacy of oral administration of different doses of CK15 soft capsules for 4 consecutive weeks in the treatment of patients with chronic kidney disease stage 5 undergoing hemodialysis and SHPT 2. To evaluate the PK characteristics of CK15 soft capsules in patients with chronic kidney disease stage 5 undergoing hemodialysis 3. To provide a basis for determining the dosing regimen and dosage for Phase II clinical trials

Start Date14 Jun 2021

Sponsor / Collaborator

Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.

[+1]

CTR20180848 / CompletedPhase 1

替诺福韦十八烷氧乙酯在健康受试者中单次给药的安全性和药代动力学Ia期临床研究

[Translation] Phase Ia clinical study on the safety and pharmacokinetics of single-dose tenofovir disoproxil fumarate in healthy subjects

1.评价替诺福韦十八烷氧乙酯在健康受试者中单次给药的安全性； 2.评价替诺福韦十八烷氧乙酯在健康受试者中单次给药的药代动力学特征。

[Translation]

1. To evaluate the safety of a single dose of tenofovir disoproxil fumarate in healthy subjects. 2. To evaluate the pharmacokinetic characteristics of a single dose of tenofovir disoproxil fumarate in healthy subjects.

Start Date12 Dec 2019

Sponsor / Collaborator

Institute of Pharmaceutical Biotechnology, Chinese Academy of Medical Sciences

[+3]

CTR20191150 / RecruitingPhase 1

CK15软胶囊在健康受试者中单剂量及多剂量给药的安全性、药代动力学和药效动力学以及进食影响研究

[Translation] Safety, pharmacokinetics, pharmacodynamics and food effect of single-dose and multiple-dose CK15 soft capsules in healthy subjects

1.评价CK15软胶囊在健康受试者中单剂量给药和多剂量给药的安全性及耐受性 2.明确CK15软胶囊的安全剂量范围 3.评价CK15软胶囊在健康受试者中的药代动力学及药效动力学特征 4.评价进食对CK15软胶囊在健康受试者中的药代动力学特征的影响

[Translation]

1. Evaluate the safety and tolerability of single-dose and multiple-dose CK15 soft capsules in healthy subjects 2. Determine the safe dose range of CK15 soft capsules 3. Evaluate the pharmacokinetic and pharmacodynamic characteristics of CK15 soft capsules in healthy subjects 4. Evaluate the effect of food intake on the pharmacokinetic characteristics of CK15 soft capsules in healthy subjects

Start Date10 Jun 2019

Sponsor / Collaborator

Xinkai Medicine and Chemical Intermediates (Shanghai) Co., Ltd.

[+1]

100 Clinical Results associated with Xinkaiyiyao Science & Technology Shanghai Co. Ltd.

Login to view more data

0 Patents (Medical) associated with Xinkaiyiyao Science & Technology Shanghai Co. Ltd.

Login to view more data

100 Deals associated with Xinkaiyiyao Science & Technology Shanghai Co. Ltd.

Login to view more data

100 Translational Medicine associated with Xinkaiyiyao Science & Technology Shanghai Co. Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Dec 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 1 Clinical

1

2

Phase 2 Clinical

Login to view more data

Current Projects

Drug(Targets)	Indications	Global Highest Phase

Teriflunomide Sodium ( DHODH )	Systemic Lupus Erythematosus More	Phase 2
CK15 ( VDR )	Hyperparathyroidism, Secondary More	Phase 2
Octadecyloxyethyl-tenofovir ( RT )	HIV Infections More	Phase 1